The predictive value of BRCA1 and BRCA2 mutation testing

Genetic Testing

Volumn 4, Issue 1, 2000, Pages 45-48

  Bansal, A ^a   Critchfield, G C ^b   Frank, T S ^b   Reid, J E ^b   Thomas, A ^b   Deffenbaugh, A M ^b   Neuhausen, S L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Myriad Genetic Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PREDICTION;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; EVALUATION STUDIES; FEMALE; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS;

EID: 0034087696     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/109065700316462     Document Type: Article

References (21)

1. AMERICAN CANCER SOCIETY. (1998). Cancer Facts and Figures. (American Cancer Society, Atlanta, GA).
2. ASCO. (1996). Statement of the American Society of Clinical Oncology: genetic testing for breast cancer susceptibility. J. Clin. Oncol. 14, 1730-1736.
3. BERRY, D.A., PARMIGIANI, G., SANCHEZ, J., SCHILDKRAUT, J., and WINER, E. (1997). Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J. Natl. Cancer Inst. 89, 227-238.
4. CLAUS, E.B., SCHILDKRAUT, J.M., THOMPSON, W.D., and RISCH, N.J. (1996). The genetic attributable risk of breast and ovarian cancer. Cancer 77, 2318-2324.
5. COUCH, F.J., DESHANO, M.L., BLACKWOOD, M.A., CALZONE, K., STOPFER, J., CAMPEAU, L., GANGULY, A., REBBECK, T., and WEBER, B.L. (1997). BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N. Engl. J. Med. 336, 1409-1415.
6. FORD, D., EASTON, D.F. and, PETO, J. (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am. J. Hum. Genet. 57, 1457-1462.
7. FORD, D., EASTON, D.F., BISHOP, D.T., NAROD, S.A., and GOLDGAR, D.E. (1994). Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343, 692-695.
8. FORD, D., EASTON, D.F., STRATTON, M., NAROD, S., GOLDGAR, D., DEVILEE, P., BISHOP, D.T., WEBER, B., LENOIR, G., CHANG-CLAUDE, J., SOBOL, H., TEARE, M.D., STRUEWING, J., ARASON, A., SCHERNECK, S., PETO, J., REBBECK, T.R., TONIN, P., NEUHAUSEN, S., BARKARDOTTIR, R., EYFJORD, J., LYNCH, H., PONDER, B.A., GAYTHER, S.A., ZELADA-HEDMAN, M., et al. (1998). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62, 676-689.
9. FRANK, T.S., MANLEY, S.A., OLOPADE, O.I., CUMMINGS, S., GARBER, J.E., BERNHARDT, B., ANTMAN, K., RUSSO, D., WOOD, M.E., MULLINEAU, L., ISAACS, C., PESHKIN, B., BUYS, S., VENNE, V., ROWLEY, P.T., LOADER, S., OFFIT, K., ROBSON, M., HAMPEL, H., BRENER, D., WINER, E.P., CLARK, S., WEBER, B., STRONG, L.C., THOMAS, A., et al. (1998). Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J. Clin. Oncol. 16, 2417-2425.
10. GALEN, R.S., and GAMBINO, S.R. (1975). Beyond Normality: The Predictive Value and Efficiency of Medical Diagnoses. (Wiley, New York).
11. HOPPER, J.L., SOUTHEY, M.C., DITE, G.S., JOLLEY, D.J., GILES, G.G., McCREDIE, M.R., EASTON, D.F., and VENTER, D.J. (1999). Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol. Biomarkers Prev. 8, 741-747.
12. MIKI, Y., SWENSEN, J., SHATTUCK-EIDENS, D., FUTREAL, P.A., HARSHMAN, K., TAVTIGIAN, S., LIU, Q., COCHRAN, C., BENNETT, L.M., DING, W., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCAl. Science 266, 66-71.
13. MYRIAD GENETICS INC. http:/www.myriad.com.
14. NELSON, N.J. (1996). Caution guides genetic testing for hereditary cancer genes. J. Natl. Cancer Inst. 88, 70-72.
15. NEUHAUSEN, S., GILEWSKI, T., NORTON, L., TRAN, T., McGUIRE, P., SWENSEN, J., HAMPEL, H., BORGEN, P., BROWN, K., SKOLNICK, M., SHATTUCK-EIDENS, D., JHANWAR, S., GOLDGAR, D., and OFFIT, K. (1996). Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genet. 13, 126-128.
16. OFFIT, K., GILEWSKI, T., McGUIRE, P., SCHLUGER, A., HAMPEL, H., BROWN, K., SWENSEN, J., NEUHAUSEN, S., SKOLNICK, M., NORTON, L., and GOLDGAR, D. (1996) Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 347, 1643-1645.
17. PETO, J., COLLINS, N., BARFOOT, R., SEAL, S., WARREN, W., RAHMAN, N., EASTON, D.F., EVANS, C., DEACON, J., and STRATTON, M.R. (1999). Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl. Cancer Inst. 91, 943-949.
18. SHATTUCK-EIDENS, D., OLIPHANT, A., McCLURE, M., McBRIDE, C., GUPTE, J., RUBANO, T., PRUSS, D., TAVTIGIAN, S.V., TENG, D.H., ADEY, N., STAEBELL, M., GUMPPER, K., LUNDSTROM, R., HULICK, M., KELLY, M., HOLMEN, J., LINGENFELTER, B., MANLEY, S., FUJIMURA, F., LUCE, M., WARD, B., CANNON-ALBRIGHT, L., STEELE, L., OFFIT, K., THOMAS, A., et al. (1997). BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. J. Am. Med. Assn. 278, 1242-1250.
19. STRUEWING, J.P., HARTGE, P., WACHOLDER, S., BAKER, S.M., BERLIN, M., McADAMS, M., TIMMERMAN, M.M., BRODY, L.C., and TUCKER, M.A. (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med. 336, 1401-1408.
20. TAVTIGIAN, S.V., SIMARD, J., ROMMENS, J., COUCH, F., SHATTUCK-EIDENS, D., NEUHAUSEN, S., MERAJVER, S., THORLACIUS, S., OFFIT, K., STOPPA-LYONNET, D., BELANGER, C., BELL, R., BERRY, S., BOGDEN, R., CHEN, Q., DAVIS, T., DUMONT, M., FRYE, C., HATTIER, T., JAMMULAPATI, S., JANECKI, T., JIANG, P., KEHRER, R., LEBLANC, J.F., GOLDGAR, D.E., et al. (1996). The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genet. 12, 333-337.
21. WOOSTER, R., BIGNELL, G. LANCASTER, J., SWIFT, S., SEAL, S., MANGLON, J., COLLINS, N., GREGORY S., GUMBS, C., MICKLEM, G., BARFOOT, R., HANOUDI, R., PATEL, S., RICE, C., BIGGS, P., HASHIM, Y., SMITH, A., CONNOR, F., ARASON, A., GUDMUNDSSON, J., FICENCE, D., KELSEL, D., FORD, D., TONIN, P., BISHOP, D.T., SPURR, N.K., PONDER, B.A.J., EELES, R., PETO, J., DEVILEE, P., CORNELISSE, C., LYNCH, H., NAROD, S., OENOIR, G., EGLISSON, V., BARKADOTTLR, R.B., EASTON, D.F., BENTLEY, D.R., FUTREAL, P.A., ASHWORTH, A., and STRATTON, M.R., (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792.